Synthetic Peptides Induce a Cytotoxic Response against Human Papillomavirus Type-18
- 1 July 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 82 (1), 77-83
- https://doi.org/10.1006/gyno.2001.6205
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Proteasomes and Antigen ProcessingAdvances in Immunology, 1997
- Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitopeAmerican Journal of Obstetrics and Gynecology, 1996
- ANOGENITAL PAPILLOMAVIRUS INFECTION AND NEOPLASIA IN IMMUNODEFICIENT WOMENObstetrics and Gynecology Clinics of North America, 1996
- THE GENETIC PROGRAM OF GENITAL HUMAN PAPILLOMAVIRUSES IN INFECTION AND CANCERObstetrics and Gynecology Clinics of North America, 1996
- Cancer of the Uterine CervixNew England Journal of Medicine, 1996
- Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumorsEuropean Journal of Immunology, 1995
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 moleculesCell, 1993
- Estimates of the worldwide incidence of eighteen major cancers in 1985International Journal of Cancer, 1993